US FDA accepts New Drug Application for umbralisib for previously treated marginal zone lymphoma and follicular lymphoma

Umbralisib is an investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon. The marginal zone lymphoma indication has been accepted for priority review, under Breakthrough therapy designation; the follicular lymphoma indication will undergo standard review.


Biospace Inc.